Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

BGC Group Inc., a financial firm controlled by the billionaire Lutnick family, bought brokerage OTC Global Holdings for $325 ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... mostly powered by a concentrated group of major tech and communication companies, commonly known ...

Vertex Pharmaceuticals (VRTX) will release its next Annual Report on n/a. Vertex Pharmaceuticals's (VRTX) last annual report was released on n/a. DISCLOSURE: InvestSMART Group Limited employees may ...

CNBC reported that Tim Opler, a managing director in Stifel’s global healthcare group, said the following ... in this narrow indication in the US. Vertex Pharmaceuticals Incorporated (NASDAQ ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals' products are constantly in high demand. The company's portfolio should help drive revenue growth for a while. It also has an exciting pipeline that will help it diversify ...

Overview: Vertex, Inc. offers enterprise tax technology ... Operations: The company's revenue segment is primarily derived from Atour Group, which generated CN¥6.67 billion.

Optum Rx, a pharmacy benefit manager owned by one of the country’s largest insurance companies, UnitedHealth Group, has added a new ... the biotechnology juggernaut Vertex Pharmaceuticals, has ...